Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: Vaginal Fluid Collection for Endometrial Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid.
Primary outcome (registry wording): Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within vaginal fluid in a larger, more diverse cohort.
Who it is for (from inclusion criteria)
Ages 18 Years to any
Women only
Patients will be ≥45 years of age and meet one of the following criteria:
Abnormal uterine bleeding
Postmenopausal bleeding
Patients ages 18 - 44 years of age and meet these criteria
One risk factor for endometrial cancer (body-mass index (BMI) ≥30 or PCOS or Tamoxifen use)
Who the registry excludes
Current known pregnancy diagnosis
Any prior pelvic or vaginal radiotherapy
Any prior cancer (except basal cell skin cancer) within the past 5 years
Chemotherapy within the past 5 years
Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia
Current biopsy-proven endometrial cancer or endometrial hyperplasia
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.
Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States.
This study wants to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT05051722?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT05051722?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.